Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients.

Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Abstract Text:

BACKGROUND: Several studies have supported the hypothesis that the concept of immuno-surveillance would not be effective in cancer patients. One reason for suppression of antitumor immunity may be attributed to immune impairment of T-lymphocytes, which extends beyond the tumor-microenvironment and might effect the peripheral blood. Therefore the aim of this study was to investigate the expression of immunoregulatory antigens in peripheral blood lymphocytes of primary breast cancer patients in comparison with healthy donors. MATERIALS AND METHODS: The peripheral blood immune status of 61 patients with primary breast cancer was analysed by FACS-analysis. The different lymphocytic subpopulations were identified by intracellular/extracellular monoclonal antibodies in three-color flow cytometry. The distribution was compared to age-matched healthy female donors (n = 29). RESULTS: The expression of TCR zeta-chain, an important signal complex for T-cell activation and functional integrity of specific immune response, was significantly reduced in the cytotoxic specific T-cell population. Cytotoxic T-cells (CD3+/CD8+) also showed a down-regulation of CD28, the important ligand to the co-stimulatory molecule CD80 (B7.1) on antigen-presenting cells. Moreover, breast cancer patients had significantly more CD95 (FAS) expressing cytotoxic T-cells than their healthy counterparts (p < 0.05). CONCLUSION: The significant up-regulation of CD95 and down-regulation of TCR zeta and CD28 in peripheral cytotoxic T-cells of breast cancer patients leads to the hypothesis of systemic immunosuppression, which could open the door for tumor cell dissemination via the blood stream and which is the subject of ongoing studies.

Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Anticancer research

VOLUME: 28

Page Numbers: 779-84

Journal Abbreviation: Anticancer Res.

ISSN: 0250-7005

DAY: 29

MONTH: 05

YEAR: 2008

Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8102988

Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients.

AFFILIATION: Department of Obstetrics and Gynecology, University of Tuebingen, 72076 Tuebingen, Germany. ines.gruber@med.uni-tuebingen.de

Country: Greece

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Anticancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Down-regulation of CD28, TCR-zeta zeta and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients Related Publications

• Acute twin-twin transfusion syndrome: a case report.
• Changes in tumour biological markers during primary systemic chemotherapy (PST).
• Disturbed cortisol secretion in man: contrasting Cushing's disease and endogenous depression.
• Dose-dependent influences on electrophysiological signs of attention in humans after neuropeptide ACTH 4-10.
• Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients.
• Epidemiology and natural course of social fears and social phobia.
• Glucocorticoid influences on the auditory brain-stem responses in man.
• Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.
• Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients.
• Tumor cell dormancy: implications for the biology and treatment of breast cancer.